A phase Ib study of pertuzumab, a recombinant humanised antibody to HER2, and docetaxel in patients with advanced solid tumours

British Journal of Cancer

Volumn 97, Issue 10, 2007, Pages 1338-1343

  Attard, G ^a   Kitzen, J ^b   Blagden, S P ^a   Fong, P C ^a   Pronk, L C ^c   Zhi, J ^c   Zugmaier, G ^c   Verweij, J ^b   De Bono, J S ^a,d   De Jonge, M ^b  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^b ERASMUS MEDICAL CENTER   (Netherlands)

^c F HOFFMANN LA ROCHE LTD   (Switzerland)

^d INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

Docetaxel; HER dimerisation inhibitors; Pertuzumab; Phase I

Indexed keywords

DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; LOPERAMIDE; PERTUZUMAB;

ABDOMINAL PAIN; ADULT; ADVANCED CANCER; AGED; AREA UNDER THE CURVE; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER PATIENT; CANDIDIASIS; CHEMOTHERAPY INDUCED EMESIS; CLINICAL PROTOCOL; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYSTITIS; DEPRESSION; DIARRHEA; DISEASE ACTIVITY; DRUG BLOOD LEVEL; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG DOSE SEQUENCE; DRUG WITHDRAWAL; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HEAD AND NECK CANCER; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; LOADING DRUG DOSE; LOWER RESPIRATORY TRACT INFECTION; LUNG CANCER; MALE; MAXIMUM TOLERATED DOSE; MELANOMA; MONOTHERAPY; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NEUROPATHY; OVARY CANCER; PANCREAS CANCER; PARAGANGLIOMA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PROSTATE CANCER; RECOMMENDED DRUG DOSE; RETROPERITONEAL TUMOR; SIDE EFFECT; SOLID TUMOR; STOMATITIS; TREATMENT OUTCOME; URINARY TRACT INFECTION;

ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; COHORT STUDIES; DISEASE PROGRESSION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; DRUG TOXICITY; FEMALE; FOLLOW-UP STUDIES; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOPLASMS; RECEPTOR, ERBB-2; RECOMBINANT PROTEINS; TAXOIDS; TIME FACTORS; TREATMENT OUTCOME;

EID: 36148966170     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/sj.bjc.6604043     Document Type: Article

References (18)

1. Adams CW, Allison DE, Flagella K, Presta L, Clarke J, Dybdal N, McKeever K, Sliwkowski MX (2006) Humanization of a recombinant monoclonal antibody to produce a therapeutic HER dimerization inhibitor, pertuzumab. Cancer Immunol Immunother 6: 717-727
2. Agus DB, Gordon MS, Taylor C, Natale RB, Karlan B, Mendelson DS, Press MF, Allison DE, Sliwkowski X, Lieberman G, Kelsey SM, Fyfe G (2005) Phase I clinical study of pertuzumab, a novel HER dimerization inhibitor, in patients with advanced cancer. J Clin Oncol 23: 2534-2543
3. Blagden SP, Kaye SB (2005) Docetaxel in the management of ovarian cancer. Expert Rev Anticancer Ther 5: 203-214
4. Bruno R, Hille D, Riva A, Vivier N, ten Bokkel Huinnink WW, van Oosterom AT, Kaye SB, Verweij J, Fossella FV, Valero V, Rigas JR, Seidman AD, Chevallier B, Fumoleau P, Burris HA, Ravdin PM, Sheiner LB (1998) Population pharmacokinetics/pharmacodynamics of docetaxel in phase II studies in patients with cancer. J Clin Oncol 16: 187-196
5. Bubley GJ, Carducci M, Dahut W, Dawson N, Daliani D, Eisenberger M, Figg WD, Freidlin B, Halabi S, Hudes G, Hussain M, Kaplan R, Myers C, Oh W, Petrylak DP, Reed E, Roth B, Sartor O, Scher H, Simons J, Sinibaldi V, Small EJ, Smith MR, Trump DL, Wilding G (1999) Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: Recommendations from the Prostate-Specific Antigen Working Group. J Clin Oncol 17: 3461-3467
6. De Bono JS, Bellmunt J, Attard G, Droz JP, Miller K, Flechon A, Steinberg C, Parker C, Zugmaier G, Gimenez V, Cockey L, Mason M, Graham J (2007) An open label phase II study to evaluate the efficacy and safety of two doses of pertuzumab in castrate chemotherapy-naïve patients with hormone refractory prostate cancer. J Clin Oncol 25: 257-262
7. Gordon MS, Matei D, Aghajanian C, Matulonis UA, Brewer M, Fleming GF, Hainsworth JD, Garcia AA, Pegram MD, Schilder RJ, Cohn DE, Roman L, Derynck MK, Ng K, Lyons B, Allison DE, Eberhard DA, Pham TQ, Dere RC, Karlan BY (2006) Clinical activity of pertuzumab (rhuMAb 2C4), a HER dimerization inhibitor, in advanced ovarian cancer: potential predictive relationship with tumor HER2 activation status. J Clin Oncol 24: 4324-4332
8. Hanahan D, Weinberg RA (2000) The hallmarks of cancer. Cell 100: 57-70
9. Johnson BE, Janne PA (2006) Rationale for a phase II trial of pertuzumab, a HER-2 dimerization inhibitor, in patients with non-small cell lung cancer. Clin Cancer Res 12: 4436s-4440s
10. Laux I, Jain A, Singh S, Agus DB (2006) Epidermal growth factor receptor dimerization status determines skin toxicity to HER-kinase targeted therapies. Br J Cancer 94: 85-92
11. Ng CM, Lum BL, Gimenez V, Kelsey S, Allison D (2006) Rationale for fixed dosing of pertuzumab in cancer patients based on population pharmacokinetic analysis. Pharm Res 23: 1275-1284
12. Pinkas-Kramarski R, Shelly M, Glathe S, Ratzkin BJ, Yarden Y (1996) Neu differentiation factor/neuregulin isoforms activate distinct receptor combinations. J Biol Chem 271: 19029-19032
13. Reid A, Vidal L, Shaw H, De Bono J (2007) Dual inhibition of ErbB1 (EGFR/HER1) and ErbB2 (HER2/neu). Eur J Cancer 43: 481-489
14. Rowinsky EK, Donehower RC (1991) The clinical pharmacology and use of antimicrotubule agents in cancer chemotherapeutics. Pharmac Ther 52: 35-84
15. Rustin GJ, Bast Jr RC, Kelloff GJ, Barrett JC, Carter SK, Nisen PD, Sigman CC, Parkinson DR, Ruddon RW (2004) Use of CA-125 in clinical trial evaluation of new therapeutic drugs for ovarian cancer. Clin Cancer Res 10: 3919-3926
16. Sundaresan S, Roberts PE, King KL, Sliwkowski MX, Mather JP (1998) Biological response to ErbB ligands in nontransformed cell lines correlates with a specific pattern of receptor expression. Endocrinology 139: 4756-4764
17. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organisation for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92: 205-216
18. Walshe JM, Denduluri N, Berman AW, Rosing DR, Swain SM (2006) A phase II trial with trastuzumab and pertuzumab in patients with HER2-overexpressed locally advanced and metastatic breast cancer. Clin Breast Cancer 6: 535-539